Education
About Us
Working with TipRanks
Follow Us
Cencora, Inc. (COR)
:COR
COR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$218.65 - $310.00
Previous CloseN/A
Volume440.68K
Average Volume (3M)1.61M
Market Cap
$59.78B
Enterprise Value$64.73B
Total Cash (Recent Filing)$2.23B
Total Debt (Recent Filing)$8.24B
Price to Earnings (P/E)31.7
Beta0.17
Next Earnings
Nov 06, 2025EPS Estimate
3.79Last Dividend Ex-Date
Aug 15, 2025Dividend Yield0.74%
Share Statistics
EPS (TTM)4.00
Shares Outstanding193,877,880
10 Day Avg. Volume2,102,663
30 Day Avg. Volume1,612,561
Financial Highlights & Ratios
PEG Ratio-2.51
Price to Book (P/B)69.17
Price to Sales (P/S)0.15
P/FCF Ratio14.91
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue0.20
Enterprise Value/Gross Profit6.67
Enterprise Value/Ebitda16.14
Forecast
1Y Price Target
$333.89Price Target Upside11.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceManagement raised its full-year adjusted EPS guidance, indicating confidence in future performance.
Healthcare Segment PerformanceUS Healthcare adjusted operating income growth estimate exceeds the company's long-term growth targets, suggesting strong momentum.
Long-term Growth ProspectsLong-term fundamentals, including exposure to oncology, generics, and biosimilars, remain attractive and are expected to provide meaningful upside.
Bears Say
Growth DecelerationThe expected guidance for FY26 could pressure shares over the near term due to a potential growth deceleration.
Investor ExpectationsManagement will likely set its FY26 US HC growth guide in line with its long-term growth targets of 5-8%, which could disappoint investors expecting a higher consensus of 9%.
Stock Valuation ConcernsThe lack of upside catalysts in the near term and shares trading near all-time highs suggest shares likely remain range-bound.
Cencora News
COR FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Cencora, Inc. lowest stock price was $218.65 and its highest was $310.00 in the past 12 months.
What is Cencora, Inc.’s market cap?
Cencora, Inc.’s market cap is $59.78B.
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on Aug 06, 2025. The company reported $4 earnings per share for the quarter, beating the consensus estimate of $3.848 by $0.152.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. pays a Quarterly dividend of $0.55 which represents an annual dividend yield of 0.74%. See more information on Cencora, Inc. dividends here
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 3.79.
How many shares outstanding does Cencora, Inc. have?
Cencora, Inc. has 193,877,880 shares outstanding.
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of $4 in its last earnings report, beating expectations of $3.848. Following the earnings report the stock price went down -2.93%.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in COR
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$333.89 (11.74% Upside)
$333.89 (11.74% Upside)
Blogger Sentiment
Bullish
COR Sentiment 70%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 0.3%
Last 30 Days ▲ 0.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.85%
12-Months-Change
Fundamentals
Return on Equity
130.60%
Trailing 12-Months
Asset Growth
10.76%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
COR Company Deck
COR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cencora demonstrated strong financial performance and raised its fiscal guidance due to excellent execution in its U.S. Healthcare Solutions segment. However, challenges in the International Healthcare Solutions segment and increased net interest expenses pose concerns. Despite these challenges, the positive aspects significantly outweigh the negative, particularly due to strong specialty performance and increased revenue and profit.View all COR earnings summariesCOR Revenue Breakdown
89.54% U.S. Healthcare Solutions
10.46% International Healthcare Solutions
COR Stock 12 Month Forecast
Average Price Target
$333.89
▲(11.74% Upside)
Technical Analysis
Ownership Overview
6.78% Insiders
27.20% Mutual Funds
20.08% Other Institutional Investors
20.13% Public Companies and Individual Investors
Options Prices
Currently, No data available
---